Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Alexander M. Menzies(The University of Sydney), Georgina V. Long(The University of Sydney), Annie Wong(Peter MacCallum Cancer Centre), Douglas B. Johnson(Vanderbilt University Medical Center), Zeynep Eroglu(Moffitt Cancer Center), John Park(California Baptist University), Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre), Shahneen Sandhu(The University of Melbourne), Jessica C. Hassel(German Cancer Research Center), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Jennifer L. McQuade(The University of Texas MD Anderson Cancer Center), Matteo S. Carlino(The University of Sydney), Antoni Ribas(University of California, Los Angeles), Katy K. Tsai(University of California, San Francisco), Victoria Atkinson(Greenslopes Private Hospital), Ryan J. Sullivan(Dana-Farber Cancer Institute), Sangeetha Ramanujam(The University of Sydney), Alexander Guminski(The University of Sydney)
Cited by 822
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k